23 and me glp-1 23andMe Research Team Publishes Study on Medication Response in Nature | Adam Auton posted on the topic Log in and start discovering what your DNA says about you. Unlocking the Genetics of GLP-1

peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events

Bottom line: these drugs overpromise and can make medium-term weight gain worse if you stop (which half of people do within a year in real-world data)

This is predominantly due to the side chain chemistry of the residue at the position equivalent to Glu9 of GLP-1

Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request